Transferrin receptor binding valency determines the circulating half-life and weight-loss efficacy of Fc-FGF21 in TfR-humanized mice
This study demonstrates that while engineering Fc-FGF21 to bind the human transferrin receptor (hTfR) aims to enhance blood-brain barrier transport, the resulting bivalent hTfR engagement in humanized mice drastically shortens the protein's circulating half-life and abolishes its weight-loss efficacy, highlighting a critical design trade-off where systemic clearance by the shuttle receptor compromises the therapeutic activity of metabolic hormones.